A placebo-controlled, double-blind Phase 1 clinical trial of SRK-015 for Spinal Muscular Atrophy
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
At a glance
- Drugs SRK-015 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man
- 08 Aug 2018 According to a Scholar Rock media release, dosing has completed in the single-ascending dose portion of the study and has advanced to the multiple-ascending dose portion of the study.
- 31 May 2018 Status changed from planning to recruiting, as reported in a Scholar Rock media release.
- 31 May 2018 According to the Scholar Rock media release, the company has completed dosing of the first cohort and is continuing enrolment of healthy volunteers in this trial.